Which peptides are used for energy and fatigue?

The core mitochondrial compounds are MOTS-c (AMPK signaling and energy substrate use) and SS-31 (mitochondrial membrane repair), often with NAD+ for cellular energy. But fatigue frequently traces back to poor sleep or growth-hormone decline, in which case sleep-oriented (DSIP) or GH-axis (CJC-1295 + ipamorelin) compounds address the true cause. The right choice depends on why energy is low.

What is the difference between MOTS-c and SS-31?

Both are mitochondrial, but they act differently. MOTS-c is a signaling peptide that activates AMPK to improve how cells use energy and glucose. SS-31 is a structural compound that stabilizes cardiolipin in the mitochondrial membrane, protecting and repairing the machinery that produces energy. They are complementary — signaling versus structure.

Do energy peptides actually give you more energy?

They are not stimulants and do not create an immediate energy 'hit.' They work by improving the underlying mitochondrial and metabolic machinery, so any benefit builds over weeks and depends heavily on identifying the real driver of fatigue first — sleep, hormones, or mitochondrial function.

Should I rule out sleep before using energy peptides?

Yes. A clinician evaluates sleep as a root cause of fatigue before assuming a mitochondrial problem. If poor sleep is driving low energy, treating the sleep issue — sometimes with a compound like DSIP or a GH-axis pairing — resolves the fatigue that mitochondrial compounds alone would not.

Energy & Mitochondrial Peptides — Re…

Name: Energy & Mitochondrial Peptides — Research Hub
Creator: Dr. Scott DelBoccio, DMD

The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.

View the Index →

Why This Hub Exists

"Give me energy" is the wrong request

The market sells "energy peptides" like they're a stronger cup of coffee. They aren't. None of these compounds is a stimulant — none produces an immediate lift. They work by repairing and re-tuning the machinery that makes energy, over weeks. Which means the only question that matters is why your energy is low in the first place, because the answer changes the compound entirely.

The core ideaLow energy has three common drivers — mitochondrial, hormonal (GH-axis), and sleep. Chase the wrong one and nothing works. A clinician rules out sleep and hormones before assuming the mitochondria are the problem.

The Landscape

The compounds, by role

Anchor · Mitochondrial

MOTS-c

Mitochondrial-derived peptide · AMPK signaling

The primary metabolic-energy signal. Activates AMPK to improve how cells use glucose and energy substrates. The default anchor when the driver is genuinely metabolic.

Anchor · Mitochondrial

SS-31

Cardiolipin stabilizer · membrane repair

Structural, not signaling — stabilizes the mitochondrial membrane (cardiolipin) that houses the energy machinery. Pairs with MOTS-c: one tunes, one repairs.

Conditional

NAD+

Coenzyme · cellular energy & repair

Added when longevity or deep cellular-energy depletion is the context — sirtuin activation, DNA repair. Common in 90-day and premium energy protocols.

Conditional

CJC-1295 + Ipamorelin

GH axis · when fatigue is hormonal

When fatigue traces to poor sleep or GH-axis decline — a very common pattern — restoring GH pulsatility addresses the true cause. Not a mitochondrial fix, a hormonal one.

Conditional

DSIP

Sleep peptide · when sleep is the driver

When poor sleep is the root cause of the energy deficit, DSIP targets sleep quality directly — because you cannot supplement your way out of a sleep problem.

Conditional

Semax

Cognitive · when it's brain fog, not fatigue

When the complaint is really cognitive fatigue or brain fog rather than physical exhaustion, Semax addresses the cognitive dimension. Different problem, different tool.

The Differentiator

Root cause decides the compound

This is the reasoning that separates a clinician-built plan from a "try an energy peptide" guess. Same symptom — low energy — but the trigger routes to a completely different compound:

Fatigue Root-Cause Logic

The driver behind the fatigue determines what actually gets used.

If low energy + poor sleep

→

Treat sleep first — DSIP and/or GH-axis (CJC + ipamorelin). Sleep is the root cause.

If low energy + metabolic markers

→

MOTS-c + SS-31 — genuine mitochondrial root cause.

If low energy + brain fog

→

Add Semax — the complaint is cognitive, not physical.

If low energy + age 45+ / longevity focus

→

Add NAD+ — cellular-energy depletion dimension.

The rule that saves people money: always evaluate sleep as the root cause of fatigue before assuming a mitochondrial issue. Most "mitochondrial" fatigue is actually a sleep or hormone problem wearing a disguise.

Mechanism, Plainly

MOTS-c and SS-31 — signal vs. structure

MOTS-c tunes how cells use energy

A mitochondrial-derived peptide that activates AMPK — the cell's master metabolic switch — improving glucose handling and energy-substrate use. It's a signal that tells the metabolism to run more efficiently.

SS-31 protects the machinery itself

Stabilizes cardiolipin, a lipid in the inner mitochondrial membrane essential to energy production. Where MOTS-c tunes the signal, SS-31 repairs and protects the structure — which is why they're paired.

NAD+ fuels the repair and longevity pathways

NAD+ is a coenzyme central to energy metabolism, DNA repair, and sirtuin activation. It declines with age, and restoring it supports the same cellular-energy machinery from a different angle.

None of these is a stimulant

There's no jolt. Benefits build over weeks as the underlying machinery improves. If someone promises an instant energy hit from these, they're describing a stimulant, not a mitochondrial compound.

Evidence Snapshot

What the research shows

Compound	Mechanism	Status & evidence
MOTS-c	Mitochondrial-derived peptide; AMPK	Research compound; preclinical and mechanistic support for metabolic and energy-substrate effects.
SS-31 (elamipretide)	Cardiolipin stabilization	Investigational; clinical development in mitochondrial disease (e.g., Barth syndrome). Research use for energy/longevity is off-label extrapolation.
NAD+	Coenzyme; sirtuin/DNA repair	Widely used; mechanistic support strong, clinical outcome data for "energy" more limited than marketing implies.
DSIP	Delta sleep-inducing peptide	Research compound; sleep-quality focus. Evidence modest; best where sleep is the confirmed driver.

Honest framingMitochondrial peptides have strong mechanistic rationale and, for SS-31, real clinical development in genuine mitochondrial disease. Their use for everyday "energy" is earlier-stage and easy to oversell. The biggest lever is still correct diagnosis of why energy is low.

Safety Screen

What gets checked first

Undiagnosed fatigue. Persistent fatigue needs a real medical workup — thyroid, anemia, sleep apnea, depression — not a peptide. Ruling out treatable causes comes first.
Sleep disorders. Untreated sleep apnea will defeat any energy compound; it must be identified, not masked.
Pregnancy / breastfeeding. Research compounds suppressed — no safety data.
Syringe rules. MOTS-c, NAD+, and SS-31 are each dosed separately — never combined in one syringe (MOTS-c pH sensitivity; NAD+ and SS-31 always separate).
Source quality. Research-grade sourcing is unregulated — certificate of analysis required.

Common Questions

Energy peptide questions answered

Will these give me an energy boost like caffeine?

No. They aren't stimulants and there's no immediate hit. They improve the mitochondrial and metabolic machinery that produces energy, so any benefit develops over weeks — and only if the real driver of your fatigue is actually mitochondrial.

MOTS-c or SS-31 — which do I need?

They do different jobs and often pair. MOTS-c is signaling (AMPK, how cells use energy). SS-31 is structural (protects the mitochondrial membrane). If you're choosing one, the answer depends on whether the issue is metabolic tuning or membrane integrity — a distinction worth a clinician's read.

Why do you keep mentioning sleep?

Because most "low energy" is a sleep or hormone problem in disguise, and no mitochondrial compound fixes a sleep deficit. Evaluating sleep first is the single highest-value step — it's where the real cause usually lives.

Is NAD+ worth it for energy?

Mechanistically it's central to cellular energy, and it declines with age. But clinical outcome data specifically for "more energy" is thinner than the marketing suggests. It's most rational as part of a longevity/cellular-health strategy rather than a quick fatigue fix.

Not Sure Where You Fit?

Take the 60-second quizAnswer a few questions and get honest, clinician-built education matched to your goal — then a personalized report. No hype, no prescription. Which peptide is right for you? →

About the Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and metabolic medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every hub reflects an independent synthesis of the primary literature and the same selection logic that drives the platform's personalized reports. No products are sold on this site.

Full Disclaimer

This hub is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. The compounds discussed are research/investigational; SS-31 (elamipretide) is in clinical development for specific mitochondrial diseases and is not approved for general energy or longevity use. Persistent fatigue can signal serious medical conditions and warrants evaluation by a licensed physician before any compound is considered. PeptideReport.ai does not manufacture, sell, or endorse any preparation. Content addresses adults 21 and older. Evidence and regulatory status continue to evolve.